Alnylam Pharmaceuticals, Inc. (ALNY) Financials
Key financial figures for Alnylam Pharmaceuticals, Inc. (Q3 2026).
Alnylam Q3 2026 net product revenue rose 52% YoY to $1.29B with AMVUTTRA at $1.13B; full-year 2026 guidance reiterated; GAAP net income of $2.17B includes a $1.87B tax benefit. Total net product revenue was $1,292M (+52% YoY); total TTR revenue was $1,150M (+59%), of which AMVUTTRA was $1,130M (+65%). Total revenues were $1,458M (+17% YoY); the year-ago quarter included a $300.0M Roche milestone. GAAP net income was $2,167M ($15.72 diluted EPS), including a $1,872M income tax benefit from valuation allowance releases; income before income taxes was $296M. Non-GAAP diluted EPS was $16.26 vs FMP estimate $1.66, but it includes the same tax benefit and is not comparable to the estimate. On the outlook: FY2026 reiterated: total net product revenue $4,700M-$5,100M (TTR $4,200M-$4,500M, Rare $500M-$600M), net revenues from collaborations and royalties $575M-$625M, non-GAAP R&D and SG&A $2,700M-$2,800M. Figures are for Q3 2026, as Alnylam Pharmaceuticals, Inc. reported them.
- Revenue
- $1.5B
- Net Income
- $2.2B
- EPS
- $16.19
- Total Assets
- $8.0B
- Operating Cash Flow
- $341M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $1.5B | $2.2B | $15.72 | 23.72% | $271M |
| Q2 FY2026 | $1.3B | $164M | $1.21 | 17.93% | $41M |
| Q1 FY2026 | $1.2B | $206M | $1.51 | 23.02% | $49M |
| Q4 FY2025 | $1.1B | $186M | $1.37 | 12.01% | $140M |
| Q3 FY2025 | $1.2B | $251M | $2.14 | 29.46% | $313M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $3.7B | $314M | $2.33 | 13.51% | $465M |
| FY2024 | $2.2B | -$278M | -$2.18 | -7.87% | -$43M |
| FY2023 | $1.8B | -$440M | -$3.52 | -15.43% | $42M |
Frequently asked questions
What was Alnylam Pharmaceuticals, Inc.'s revenue last quarter?
Alnylam Pharmaceuticals, Inc. reported revenue of $1.46 billion for Q3 FY2026, up 16.7% from the same period a year earlier.
Is Alnylam Pharmaceuticals, Inc. profitable?
Yes. Alnylam Pharmaceuticals, Inc. reported net income of $2.17 billion for Q3 FY2026, a net margin of 148.64% on revenue.
How has Alnylam Pharmaceuticals, Inc.'s margin trended?
Operating margin was 23.72% in Q3 FY2026, compared with 29.46% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Alnylam Pharmaceuticals, Inc. generate?
Alnylam Pharmaceuticals, Inc. generated free cash flow of $271.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Alnylam Pharmaceuticals, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.